We conducted a phase II study in men with castration-sensitive metastatic prostate cancer to test the hypothesis that AT-101, a small molecule Bcl-2 inhibitor, has clinical activity in patients initiating androgen deprivation therapy (ADT) for metastatic prostate cancer.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Patients with metastatic prostate cancer scheduled to start, or who had recently (within 6 weeks) initiated, ADT were enrolled. ADT with a luteinizing hormone-releasing hormone agonist and bicalutamide was started 6 weeks before initiation of oral AT-101, 20 mg/day for 21 days of a 28-day cycle. The primary endpoint of the study was the percentage of patients with an undetectable prostate-specific antigen (PSA) level (≤ 0. 2 ng/mL) after 7. 5 months (1. 5 months of ADT alone plus 6 months of combined ADT and AT-101). To assess for an association between chromodomain helicase DNA binding protein 1 (CHD1) and drug sensitivity, fluorescence in situ hybridization with confocal microscopy was assessed in a subgroup of patients.
A total of 55 patients were enrolled, with median age of 61 years and a median PSA level of 27. 6 ng/dL. Of the 55 patients, 72% had a Gleason score ≥ 8. Three patients had visceral metastases, and the remaining patients had bone or nodal metastasis. An undetectable PSA level was achieved in 31% of the patients. Of the 31 patients, 12 experienced serious adverse events, 7 of which were considered related to study therapy. Most of the related adverse events were gastrointestinal and nervous system disorders. CHD1 assessment was feasible, with a nonsignificant association with therapeutic sensitivity in a small number of patients.
The combination of ADT and AT-101 did not meet the prespecified level of activity for further development of this combination.
Clinical genitourinary cancer. 2015 Sep 21 [Epub ahead of print]
Mark N Stein, Maha Hussain, Walter M Stadler, Glenn Liu, Irina V Tereshchenko, Susan Goodin, Chandrika Jeyamohan, Howard L Kaufman, Janice Mehnert, Robert S DiPaola
Rutgers Cancer Institute of New Jersey, New Brunswick, NJ. , University of Michigan, Ann Arbor, MI. , University of Chicago, Chicago, IL. , UW Carbone Cancer Center, University of Wisconsin, Madison, WI. , Rutgers Cancer Institute of New Jersey, New Brunswick, NJ. , Rutgers Cancer Institute of New Jersey, New Brunswick, NJ. , Rutgers Cancer Institute of New Jersey, New Brunswick, NJ. , Rutgers Cancer Institute of New Jersey, New Brunswick, NJ. , Rutgers Cancer Institute of New Jersey, New Brunswick, NJ. , Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.